Physician profile
Radu Jacob
NPI 1265462873
$4,475.42
in general payments reported to CMS, 2019-2025
31 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $63.98 · 2021: $194 · 2022: $584 · 2023: $575 · 2024: $2,533 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,790 · Food and Beverage: $1,703 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,789.55 |
| Food and Beverage | $1,702.73 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,968.30 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $447.57 | 2022-2025 | |
| Horizon Therapeutics Plc | $323.71 | 2021-2023 | Krystexxa |
| Amgen INC. | $263.19 | 2021-2024 | Parsabiv, Tavneos, Aranesp |
| Glaxosmithkline, LLC. | $188.37 | 2021-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.97 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $128.01 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $111.84 | 2023-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $109.13 | 2021-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $104.86 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $94.47 | 2023-2025 | Farxiga |
| Akebia Therapeutics INC | $88.59 | 2020-2024 | Vafseo |
| Novo Nordisk INC | $80.27 | 2025 | Ozempic |
| Nxstage Medical, INC. | $58.47 | 2019 | |
| Xeris Pharmaceuticals, INC. | $50.91 | 2023-2025 | Keveyis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $45.05 | 2023 | Lupkynis |
| Vifor Pharma, INC. | $44.58 | 2023-2024 | Veltassa, Korsuva |
| Shire North American Group INC | $41.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $37.79 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $34.96 | 2022 | |
| Cvrx, INC. | $33.05 | 2023 | Barostim Neo System |
| Shield Therapeutics INC | $24.01 | 2024 | |
| Fresenius USA Marketing, INC. | $18.29 | 2024 | |
| Invivyd INC | $17.64 | 2025 | Pemgarda |
| Genzyme Corporation | $16.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.45 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radu Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.